{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:06:00Z","timestamp":1772136360106,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-85317-3","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T23:31:12Z","timestamp":1736119872000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B"],"prefix":"10.1038","volume":"15","author":[{"given":"Takuya","family":"Matsubara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoshi","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Omaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoriaki","family":"Komeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"85317_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000343857","volume":"3","author":"M Kawanaka","year":"2014","unstructured":"Kawanaka, M. et al. Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving long-term nucleos(t)ide analogue therapy. Liver Cancer. 3, 41\u201352 (2014).","journal-title":"Liver Cancer"},{"key":"85317_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault, N. A. et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63, 261\u2013283 (2016).","journal-title":"Hepatology"},{"key":"85317_CR3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu & European Association for the study of the liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370\u2013398 (2017).","journal-title":"J. Hepatol."},{"key":"85317_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin, S. K. et al. Asian-pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol. Int. 10, 1\u201398 (2016).","journal-title":"Hepatol. Int."},{"key":"85317_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hepr.12108","volume":"44","author":"E Tanaka","year":"2014","unstructured":"Tanaka, E. & Matsumoto, A. Guidelines for avoiding risks resulting from discontinuation of nucleoside\/nucleotide analogs in patients with chronic hepatitis B. Hepatol. Res. 44, 1\u20138 (2014).","journal-title":"Hepatol. Res."},{"key":"85317_CR6","doi-asserted-by":"publisher","first-page":"71e9","DOI":"10.1016\/j.amjmed.2005.02.033","volume":"119","author":"Y Arase","year":"2006","unstructured":"Arase, Y. et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am. J. Med. 119, 71e9\u20137116 (2006).","journal-title":"Am. J. Med."},{"key":"85317_CR7","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1111\/apt.17222","volume":"56","author":"Q Hu","year":"2022","unstructured":"Hu, Q. et al. The efficacy and safety of adding on or switching to peginterferon \u03b1-2b in HBeAg-positive chronic hepatitis B patients with long-term entecavir treatment: a multicentre randomised controlled trial. Aliment. Pharmacol. Ther. 56, 1394\u20131407 (2022).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"85317_CR8","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/hep.30050","volume":"68","author":"S Wirth","year":"2018","unstructured":"Wirth, S. et al. Efficacy and safety of peginterferon alfa-2a (40KD) in children with chronic hepatitis B: the PEG-B-ACTIVE study. Hepatology 68, 1681\u20131694 (2018).","journal-title":"Hepatology"},{"key":"85317_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jhep.2014.08.021","volume":"62","author":"P Marcellin","year":"2015","unstructured":"Marcellin, P. et al. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. J. Hepatol. 62, 41\u201347 (2015).","journal-title":"J. Hepatol."},{"key":"85317_CR10","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1111\/j.1440-1746.2011.07051.x","volume":"27","author":"D Ratnam","year":"2012","unstructured":"Ratnam, D. et al. Efficacy and tolerability of pegylated interferon-\u03b1-2A in chronic hepatitis B: a multicenter clinical experience. J. Gastroenterol. Hepatol. 27, 1447\u20131453 (2012).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"85317_CR11","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","volume":"63","author":"GA Kim","year":"2014","unstructured":"Kim, G. A. et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 63, 1325\u20131332 (2014).","journal-title":"Gut"},{"key":"85317_CR12","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/j.1572-0241.1998.00272.x","volume":"93","author":"G Fattovich","year":"1998","unstructured":"Fattovich, G. et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European concerted action on viral hepatitis (EUROHEP). Am. J. Gastroenterol. 93, 896\u2013900 (1998).","journal-title":"Am. J. Gastroenterol."},{"key":"85317_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/apt.15108","volume":"49","author":"T Hosaka","year":"2019","unstructured":"Hosaka, T. et al. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues. Aliment. Pharmacol. Ther. 49, 457\u2013471 (2019).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"85317_CR14","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1053\/j.gastro.2019.08.028","volume":"157","author":"TC Tseng","year":"2019","unstructured":"Tseng, T. C. et al. High level of Hepatitis B Core-related Antigen Associated with increased risk of Hepatocellular Carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology 157, 1518\u20131529 (2019).","journal-title":"Gastroenterology"},{"key":"85317_CR15","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1111\/jgh.15563","volume":"36","author":"S Kaneko","year":"2021","unstructured":"Kaneko, S. et al. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients. J. Gastroenterol. Hepatol. 36, 2943\u20132951 (2021).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"85317_CR16","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3350\/cmh.2022.0434","volume":"29","author":"T Inoue","year":"2023","unstructured":"Inoue, T. et al. Hepatitis B core-related antigen: a novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy. Clin. Mol. Hepatol. 29, 851\u2013868 (2023).","journal-title":"Clin. Mol. Hepatol."},{"key":"85317_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/hepr.12902","volume":"48","author":"K Koike","year":"2018","unstructured":"Koike, K., Suyama, K., Ito, H., Itoh, H. & Sugiura, W. Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-na\u00efve chronic hepatitis B patients. Hepatol. Res. 48, 59\u201368 (2018).","journal-title":"Hepatol. Res."},{"key":"85317_CR18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti, M. et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol. Hepatol. 1, 196\u2013206 (2016).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"85317_CR19","doi-asserted-by":"publisher","first-page":"e13522","DOI":"10.1111\/tid.13522","volume":"23","author":"J Rashidi-Alavijeh","year":"2021","unstructured":"Rashidi-Alavijeh, J. et al. Safety and efficacy of tenofovir alafenamide in liver transplant recipients: a single center experience. Transpl. Infect. Dis. 23, e13522 (2021).","journal-title":"Transpl. Infect. Dis."},{"key":"85317_CR20","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1111\/jgh.14686","volume":"34","author":"S Kaneko","year":"2019","unstructured":"Kaneko, S. et al. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate. J. Gastroenterol. Hepatol. 34, 2004\u20132010 (2019).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"85317_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/hepr.13650","volume":"51","author":"S Hagiwara","year":"2021","unstructured":"Hagiwara, S. et al. Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: long-term effects from a prospective study. Hepatol. Res. 51, 767\u2013774 (2021).","journal-title":"Hepatol. Res."},{"key":"85317_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jcv.2006.01.003","volume":"35","author":"S Hochberger","year":"2006","unstructured":"Hochberger, S. et al. Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep\/COBAS TaqMan system. J. Clin. Virol. 35, 373\u2013380 (2006).","journal-title":"J. Clin. Virol."},{"key":"85317_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0166-0934(99)00039-7","volume":"80","author":"S Usuda","year":"1999","unstructured":"Usuda, S. et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J. Virol. Methods. 80, 97\u2013112 (1999).","journal-title":"J. Virol. Methods"},{"key":"85317_CR24","doi-asserted-by":"publisher","first-page":"e0262764","DOI":"10.1371\/journal.pone.0262764","volume":"17","author":"Y Uchida","year":"2022","unstructured":"Uchida, Y. et al. Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: a 144-week outcome study after switching of the nucleos(t)ide analog. PLOS ONE. 17, e0262764 (2022).","journal-title":"PLoS One"},{"key":"85317_CR25","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/apt.17107","volume":"56","author":"E Ogawa","year":"2022","unstructured":"Ogawa, E. et al. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. Aliment. Pharmacol. Ther. 56, 713\u2013722 (2022).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"85317_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","volume":"5","author":"J Choi","year":"2019","unstructured":"Choi, J. et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol. 5, 30\u201336 (2019).","journal-title":"JAMA Oncol."},{"key":"85317_CR27","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jhep.2019.03.028","volume":"71","author":"SU Kim","year":"2019","unstructured":"Kim, S. U. et al. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-na\u00efve chronic hepatitis B in South Korea. J. Hepatol. 71, 456\u2013464 (2019).","journal-title":"J. Hepatol."},{"key":"85317_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jhep.2021.09.017","volume":"76","author":"WM Choi","year":"2022","unstructured":"Choi, W. M., Yip, T. C., Lim, Y. S., Wong, G. L. & Kim, W. R. Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. J. Hepatol. 76, 186\u2013194 (2022).","journal-title":"J. Hepatol."},{"key":"85317_CR29","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1111\/jvh.13601","volume":"28","author":"HW Lee","year":"2021","unstructured":"Lee, H. W. et al. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. J. Viral Hepat. 28, 1570\u20131578 (2021).","journal-title":"J. Viral Hepat."},{"key":"85317_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/hep4.1819","volume":"6","author":"T Hosaka","year":"2022","unstructured":"Hosaka, T. et al. Ultrasensitive assay for hepatitis B core-related antigen predicts hepatocellular carcinoma incidences during entecavir. Hepatol. Commun. 6, 36\u201349 (2022).","journal-title":"Hepatol. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85317-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85317-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85317-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T10:06:44Z","timestamp":1736158004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85317-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["85317"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-85317-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5126210\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"21 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"869"}}